Gilead Moves Closer to Dominating Hep C Market

Washington Drug Letter
Gilead Sciences’ drug Sovaldi appears primed to dominate the hepatitis C market with the release of new Phase III trial data showing subjects with genotype 1 of the virus benefit from the drug, without coupling it with interferon.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00